Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13562620 | 0.86 | NPC1 (0.48) | EPHX2ALDH1A1P2RX7HDAC6NPC1 | |
| SCHEMBL13518585 | 0.82 | EPHX2 (0.44) | FAAHEPHX2ALDH1A1KDM4EKMT2A | |
| SCHEMBL29368906 | 0.74 | FAAH (0.55) | FAAHEPHX2ALDH1A1KDM4EEPHX1 | |
| SCHEMBL1937667 | 0.72 | FAAH (0.56) | FAAHEPHX2ALDH1A1KDM4EEPHX1 | |
| SCHEMBL8697982 | 0.72 | PGR (0.49) | ALDH1A1KDM4EKMT2AMEN1MAPK1 | |
| SCHEMBL29016421 | 0.71 | KMT2A (0.50) | ALDH1A1KDM4EKMT2AMEN1MAPK1 | |
| SCHEMBL19305014 | 0.70 | PGR (0.47) | ALDH1A1KMT2ARAB9A | |
| SCHEMBL1421026 | 0.69 | FAAH (1.00) | FAAHEPHX2ALDH1A1KDM4EEPHX1 | |
| SCHEMBL17414388 | 0.69 | FAAH (0.51) | FAAHEPHX2ALDH1A1KDM4EEPHX1 | |
| SCHEMBL28094059 | 0.68 | FAAH (0.50) | FAAHEPHX2ALDH1A1KDM4EEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2331495-B1 | PROCESS FOR MANUFACTURING ADAMANTANE DERIVATIVES WITH HIGH YIELD | MERZ PHARMA GMBH & CO KGAA (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8796491-B2 | Process for manufacturing adamantane derivatives with high yield | MERZ PHARMA GMBH & CO. KGAA (DE) | 2014-08-05 | — | — | US | disclosed |
| US-20110263900-A1 | PROCESS FOR MANUFACTURING ADAMANTANE DERVATIVES WITH HIGH YIELD | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-10-27 | — | — | US | disclosed |
| EP-2331495-A1 | PROCESS FOR MANUFACTURING ADAMANTANE DERIVATIVES WITH HIGH YIELD | Merz Pharma GmbH & Co. KGaA (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010015415-A1 | PROCESS FOR MANUFACTURING ADAMANTANE DERIVATIVES WITH HIGH YIELD | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263900-A1 | PROCESS FOR MANUFACTURING ADAMANTANE DERVATIVES WITH HIGH YIELD | BACE1, BACE2, APP | FAAH 285/4885EPHX2 1522/4885ALDH1A1 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.